ArticleActa haematologica2026
Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.
Article in Acta haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03948867 (Stroke Prevention With Hydroxyurea Enabled Through Research and Education), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE): A Prospective Trial to Reduce Primary Stroke in Children With Sickle Cell Anaemia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAfrican children with sickle cell anemia (SCA) often have splenomegaly with recurrent cytopenias that complicate management, rather than the splenic atrophy typically observed in SCA.
methodsWe analyzed the presence, persistence, and impact of splenomegaly in the Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE) trial (NCT03948867), an open-label trial of dose-escalated hydroxyurea to prevent stroke in Tanzanian children with SCA. Palpable splenomegaly was recorded at each visit. Annual ultrasound measurements were compared to age- and height-related references. Longitudinally, palpable splenomegaly was categorized as infrequent (present in <5% visits), intermittent (10-50% visits), or persistent (>50% visits). Adverse events (AEs) and hydroxyurea dose-limiting toxicities (DLTs) were compared using incidence rate ratios (IRRs) among the three categories.
resultsAt enrollment, splenomegaly was identified in 48/196 (25%) by palpation and 78 (40%) by ultrasound. Across 221 patient-years of treatment in 53 children, splenomegaly was intermittent in 19% and persistent in 21%. At 12 months, children with persistent splenomegaly were compared to those with infrequent splenomegaly and had achieved similar hydroxyurea dose (23.1 vs. 27.6 mg/kg/day, p = 0.136), hemoglobin (9.0 vs. 9.1 g/dL, p = 0.877), and HbF (23.8 vs. 24.3%, p = 0.481), but experienced more vaso-occlusive AE (IRR = 3.8, p value 0.122), transfusions (IRR = 7.1, p value 0.014), and DLTs (IRR = 3.2, p value 0.073).
conclusionSplenomegaly is common in Tanzanian children with SCA, often persistent, worsens clinical outcomes, and complicates hydroxyurea. Its cause remains unclear, and further investigation is urgently needed to clarify its etiology, improve its management, and ensure optimal hydroxyurea treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.